ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.10% Shs Outstand161.65M Perf Week5.63%
Market Cap2.65B Forward P/E- EPS next Y-0.56 Insider Trans-10.65% Shs Float160.88M Perf Month10.28%
Income-204.60M PEG- EPS next Q-0.19 Inst Own92.50% Short Float6.01% Perf Quarter2.77%
Sales512.40M P/S5.17 EPS this Y41.60% Inst Trans0.47% Short Ratio3.61 Perf Half Y-34.86%
Book/sh2.69 P/B6.34 EPS next Y57.30% ROA-30.80% Target Price18.88 Perf Year1.31%
Cash/sh2.81 P/C6.07 EPS next 5Y25.00% ROE-41.20% 52W Range12.24 - 28.06 Perf YTD-26.91%
Dividend- P/FCF- EPS past 5Y14.90% ROI-31.60% 52W High-37.89% Beta0.72
Dividend %- Quick Ratio4.50 Sales past 5Y94.60% Gross Margin97.10% 52W Low42.36% ATR0.82
Employees540 Current Ratio4.50 Sales Q/Q16.80% Oper. Margin-40.30% RSI (14)64.33 Volatility4.15% 5.57%
OptionableYes Debt/Eq0.00 EPS Q/Q23.10% Profit Margin-39.90% Rel Volume0.51 Prev Close17.06
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume2.68M Price17.42
Recom2.60 SMA2012.52% SMA5011.38% SMA200-14.69% Volume539,897 Change2.14%
Aug-08-22Downgrade Citigroup Buy → Neutral $19 → $15
Aug-05-22Downgrade Citigroup Buy → Neutral $19 → $15
Jun-21-22Downgrade Jefferies Buy → Underperform $25 → $10
Jun-16-22Upgrade Jefferies Hold → Buy $25
Mar-16-22Upgrade Canaccord Genuity Hold → Buy $30 → $31
Feb-09-22Upgrade H.C. Wainwright Neutral → Buy $36
Jan-05-22Upgrade Citigroup Neutral → Buy $30
Dec-21-21Downgrade Guggenheim Buy → Neutral $28
Nov-01-21Upgrade Guggenheim Neutral → Buy $23
Oct-14-21Downgrade Morgan Stanley Overweight → Equal-Weight $20
Sep-23-21Resumed Needham Hold
Jun-10-21Initiated Berenberg Hold $29
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral $43 → $18
Apr-06-21Downgrade Mizuho Buy → Neutral $37 → $25
Apr-06-21Downgrade Jefferies Buy → Hold $40 → $21
Apr-06-21Downgrade Goldman Buy → Neutral $73 → $25
Apr-06-21Downgrade Canaccord Genuity Buy → Hold $40 → $26
Apr-05-21Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21Downgrade BofA Securities Buy → Neutral
Mar-09-21Reiterated H.C. Wainwright Buy $60 → $43
Aug-09-22 01:24PM  
Aug-08-22 05:35PM  
Aug-05-22 07:55AM  
Aug-04-22 11:39PM  
Aug-01-22 10:01AM  
Jul-27-22 08:23AM  
Jul-25-22 04:05PM  
Jul-19-22 11:22AM  
Jul-18-22 04:07PM  
Jul-08-22 11:14AM  
Jun-21-22 12:07PM  
Jun-17-22 08:00PM  
Jun-16-22 03:42PM  
Jun-15-22 04:53PM  
Jun-03-22 11:31AM  
May-19-22 09:01AM  
May-05-22 10:06AM  
May-04-22 06:15PM  
May-03-22 04:05PM  
May-02-22 04:05PM  
Apr-27-22 03:03PM  
Apr-21-22 09:09AM  
Apr-19-22 05:52PM  
Apr-18-22 04:05PM  
Mar-30-22 11:30AM  
Mar-25-22 02:26PM  
Mar-22-22 09:00AM  
Mar-10-22 04:05PM  
Mar-09-22 08:30AM  
Mar-03-22 09:00AM  
Mar-01-22 09:43AM  
Feb-28-22 05:35PM  
Feb-21-22 03:00PM  
Feb-17-22 04:28AM  
Feb-16-22 09:00AM  
Feb-14-22 09:00AM  
Feb-11-22 09:00AM  
Feb-02-22 01:38PM  
Jan-13-22 11:13AM  
Jan-11-22 11:56AM  
Jan-10-22 01:20PM  
Dec-22-21 05:24PM  
Dec-21-21 04:12PM  
Dec-20-21 04:05PM  
Dec-14-21 09:00AM  
Dec-11-21 05:38AM  
Dec-08-21 08:35AM  
Dec-07-21 12:29PM  
Dec-06-21 05:23PM  
Dec-01-21 09:00AM  
Nov-26-21 03:58PM  
Nov-16-21 09:00AM  
Nov-09-21 11:08AM  
Nov-08-21 05:25PM  
Nov-02-21 09:00AM  
Nov-01-21 04:05PM  
Oct-29-21 01:35PM  
Oct-27-21 03:03PM  
Oct-25-21 09:44AM  
Oct-23-21 06:08AM  
Oct-15-21 08:25AM  
Sep-03-21 11:31AM  
Sep-02-21 09:00AM  
Sep-01-21 04:05PM  
Aug-26-21 09:55AM  
Aug-22-21 08:04AM  
Aug-06-21 04:31PM  
Aug-05-21 04:05PM  
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schneyer Mark C.EVP, Chief Financial OfficerJun 09Sale17.9165311,6953,342Jun 10 08:51 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Option Exercise0.001,89303,995Jun 10 08:51 PM
DAVIS STEPHENCEOMay 02Sale18.185,48399,69175,875May 03 08:58 PM
Stankovic Srdjan R.PresidentMay 02Sale18.182,86552,09155,188May 03 08:55 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryMay 02Sale18.1889416,25516,742May 03 08:51 PM
Teehan BrendanEVP, COO, Head of CommercialMay 02Sale18.1855210,0363,437May 03 08:47 PM
Kihara JamesPrincipal Accounting OfficerApr 08Sale27.051,02527,7262,433Apr 11 08:02 PM
Kihara JamesPrincipal Accounting OfficerFeb 23Option Exercise0.008400840Feb 25 05:45 PM
Stankovic Srdjan R.PresidentFeb 23Option Exercise0.004,919049,938Feb 25 05:41 PM
Teehan BrendanEVP, COO, Head of CommercialFeb 23Option Exercise0.001,10602,894Feb 25 05:45 PM
DAVIS STEPHENCEOFeb 23Option Exercise0.0010,945069,661Feb 25 05:40 PM
KIM AUSTIN D.EVP & General CounselFeb 23Option Exercise0.002,213015,413Feb 25 05:42 PM
KIM AUSTIN D.EVP & General CounselFeb 23Sale23.8078218,61214,631Feb 25 05:42 PM
DAVIS STEPHENCEOFeb 23Sale23.803,92893,48665,733Feb 25 05:40 PM
Teehan BrendanEVP, COO, Head of CommercialFeb 23Sale23.8047211,2342,422Feb 25 05:45 PM
Stankovic Srdjan R.PresidentFeb 23Sale23.801,50135,72448,437Feb 25 05:41 PM
Kihara JamesPrincipal Accounting OfficerFeb 23Sale23.803598,544481Feb 25 05:45 PM
DAVIS STEPHENCEOJan 06Sale23.053,71885,70058,716Jan 10 06:22 PM
Stankovic Srdjan R.PresidentJan 06Sale23.051,93744,64845,019Jan 10 06:23 PM
KIM AUSTIN D.EVP & General CounselJan 06Sale23.0557413,23113,200Jan 10 06:24 PM
Teehan BrendanEVP, COO, Head of CommercialJan 06Sale23.0553812,4011,788Jan 10 06:25 PM
Stankovic Srdjan R.PresidentNov 22Sale19.012,80353,28541,512Nov 23 06:00 PM
Stankovic Srdjan R.PresidentOct 18Sale17.411,33823,29538,065Oct 19 05:31 PM
DAVIS STEPHENCEOOct 18Sale17.412,96351,58652,906Oct 19 05:30 PM